These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Autoantibodies to tumor-associated antigens in lung cancer diagnosis. Zhang X; Liu M; Zhang X; Wang Y; Dai L Adv Clin Chem; 2021; 103():1-45. PubMed ID: 34229848 [TBL] [Abstract][Full Text] [Related]
24. Development of a multiplex autoantibody test for detection of lung cancer. Jia J; Wang W; Meng W; Ding M; Ma S; Wang X PLoS One; 2014; 9(4):e95444. PubMed ID: 24755629 [TBL] [Abstract][Full Text] [Related]
25. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer. Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790 [TBL] [Abstract][Full Text] [Related]
26. A Panel of Tumor-associated Autoantibodies for the Detection of Early-stage Breast Cancer. Hong CQ; Weng XF; Huang XC; Chu LY; Wei LF; Lin YW; Chen LY; Liu CT; Xu YW; Peng YH J Cancer; 2021; 12(9):2747-2755. PubMed ID: 33854634 [TBL] [Abstract][Full Text] [Related]
27. Autoantibody Signatures Combined with Epstein-Barr Virus Capsid Antigen-IgA as a Biomarker Panel for the Detection of Nasopharyngeal Carcinoma. Peng YH; Xu YW; Huang LS; Zhai TT; Dai LH; Qiu SQ; Yang YS; Chen WZ; Zhang LQ; Li EM; Xu LY Cancer Prev Res (Phila); 2015 Aug; 8(8):729-36. PubMed ID: 25990085 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53. Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570 [TBL] [Abstract][Full Text] [Related]
29. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition. Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603 [TBL] [Abstract][Full Text] [Related]
30. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Chapman C; Murray A; Chakrabarti J; Thorpe A; Woolston C; Sahin U; Barnes A; Robertson J Ann Oncol; 2007 May; 18(5):868-73. PubMed ID: 17347129 [TBL] [Abstract][Full Text] [Related]
31. Discovering novel lung cancer associated antigens and the utilization of their autoantibodies in detection of lung cancer. Pei L; Liu H; Ouyang S; Zhao C; Liu M; Wang T; Wang P; Ye H; Wang K; Song C; Zhang J; Dai L Immunobiology; 2020 Mar; 225(2):151891. PubMed ID: 31839396 [TBL] [Abstract][Full Text] [Related]
32. Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma. Li Y; Li CQ; Guo SJ; Guo W; Jiang HW; Li HC; Tao SC EBioMedicine; 2020 Mar; 53():102674. PubMed ID: 32113159 [TBL] [Abstract][Full Text] [Related]
33. Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules. Wang J; Shivakumar S; Barker K; Tang Y; Wallstrom G; Park JG; Tsay JC; Pass HI; Rom WN; LaBaer J; Qiu J J Thorac Oncol; 2016 Mar; 11(3):334-45. PubMed ID: 26896032 [TBL] [Abstract][Full Text] [Related]
34. Application of serum NY-ESO-1 antibody assay for early SCLC diagnosis. Yang J; Jiao S; Kang J; Li R; Zhang G Int J Clin Exp Pathol; 2015; 8(11):14959-64. PubMed ID: 26823828 [TBL] [Abstract][Full Text] [Related]
35. Neural autoantibody clusters aid diagnosis of cancer. Horta ES; Lennon VA; Lachance DH; Jenkins SM; Smith CY; McKeon A; Klein C; Pittock SJ Clin Cancer Res; 2014 Jul; 20(14):3862-9. PubMed ID: 24833664 [TBL] [Abstract][Full Text] [Related]
36. [Clinical significance and diagnostic value of Survivin autoantibody in non-small cell lung cancer patients]. Ma L; Yue W; Zhang L; Wang Y; Zhang C; Yang X Zhongguo Fei Ai Za Zhi; 2010 Jul; 13(7):706-12. PubMed ID: 20673487 [TBL] [Abstract][Full Text] [Related]
37. Rethinking Autoantibody Signature Panels for Cancer Diagnosis. Campa MJ; Gottlin EB; Herndon JE; Patz EF J Thorac Oncol; 2017 Jun; 12(6):1011-1014. PubMed ID: 28126538 [TBL] [Abstract][Full Text] [Related]
38. Simplified approaches for the development of an ELISA to detect circulating autoantibodies to p53 in cancer patients. Cressey R; Pimpa S; Chewaskulyong B; Lertprasertsuke N; Saeteng S; Tayapiwatana C; Kasinrerk W BMC Biotechnol; 2008 Feb; 8():16. PubMed ID: 18284706 [TBL] [Abstract][Full Text] [Related]
39. Diagnostic value of α-enolase expression and serum α-enolase autoantibody levels in lung cancer. Zhang L; Wang H; Dong X J Bras Pneumol; 2018; 44(1):18-23. PubMed ID: 29538538 [TBL] [Abstract][Full Text] [Related]
40. Development of an autoantibody panel for early detection of lung cancer in the Chinese population. Tong L; Sun J; Zhang X; Ge D; Li Y; Zhou J; Wang D; Hu X; Liu H; Bai C Front Med (Lausanne); 2023; 10():1209747. PubMed ID: 38089873 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]